Corrigendum: Interpretation guidance for MHRA regulatory considerations for phage therapeutic products
Carmen Coxon, Elizabeth Bell, Evelien Adriaenssens, Jason Clark, Joe Edwards, Tas Gohir, Francesca Hodges, Josh Jones, Cath Rees, Annette Sansom, Darren Smith, Mark Sutton, Clare Trippett, Dann Turner
Abstract
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBacteriophages and microbial interactions · Monoclonal and Polyclonal Antibodies Research · vaccines and immunoinformatics approaches
The authors wish to add the following disclaimer to their article:
‘This document reflects the views of subject matter experts from the Innovate UK Phage Innovation Network and the MHRA Science Campus and should not be construed to represent the official view of any given regulatory authority.’
In line with this request, the version of record will also be updated to include the disclaimer text.